Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2722 for moderate-to-severe atopic dermatitis extension study
CTR20260098Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2722 in atopic dermatitis (AD), sponsored by Nanjing Shunxin Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
TQH2722
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20260098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260098.